CN115497552A - Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application - Google Patents

Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application Download PDF

Info

Publication number
CN115497552A
CN115497552A CN202211185735.7A CN202211185735A CN115497552A CN 115497552 A CN115497552 A CN 115497552A CN 202211185735 A CN202211185735 A CN 202211185735A CN 115497552 A CN115497552 A CN 115497552A
Authority
CN
China
Prior art keywords
gastric cancer
risk
endoplasmic reticulum
reticulum stress
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202211185735.7A
Other languages
Chinese (zh)
Inventor
张一凡
陈星�
乔军
王琪
张荷艺
张升校
郝铭慧
隋玥
卢俊会
乔瑶
任洁颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Hospital of Shanxi Medical University
Original Assignee
First Hospital of Shanxi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Hospital of Shanxi Medical University filed Critical First Hospital of Shanxi Medical University
Priority to CN202211185735.7A priority Critical patent/CN115497552A/en
Publication of CN115497552A publication Critical patent/CN115497552A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20Screening of libraries
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Library & Information Science (AREA)
  • Molecular Biology (AREA)
  • Bioethics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention belongs to the technical field of tumor markers and biomedical detection, and particularly relates to a gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic genes and application thereof. The data collected from the TCGA database was used as a training set for a total of 375 gastric cancer samples and 32 paracancerous samples. And verified using 387 gastric cancer samples in the GEO database as an external verification set. 6 endoplasmic reticulum stress characteristic genes NOS3, PON1, CXCR4, MATN3, ANXA5 and SERPINE1 which are successfully screened out according to comprehensive excavation of transcription spectrum and tumor microenvironment characteristics. The prediction model shows good performance of predicting the overall survival rate of the gastric cancer in a training set and a testing set. A risk score based on 6 genes associated with endoplasmic reticulum stress may well classify gastric cancer patients into high risk, low risk populations, which may aid in the selection of clinical treatment regimens.

Description

Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application
Technical Field
The invention belongs to the technical field of tumor markers and biomedical detection, and particularly relates to a gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic genes and application thereof.
Background
Gastric cancer is the third leading cause of cancer death and the fifth most common malignant tumor worldwide, with over 100 new cases annually. China is a country with high incidence of gastric cancer, newly increased cases and death cases account for 42.6 percent and 45.0 percent of the total number of the whole world respectively, and the 5-year survival rate of the age standardization is 27.4 percent. Early symptoms of the gastric cancer sample are hidden, and the treatment effect and prognosis are poor. Most gastric cancer samples are diagnosed at an advanced stage, leading to poor overall prognosis, manifested by metastasis, high intratumoral heterogeneity and chemoresistance. Despite the rapid development of immunotherapy, targeted therapy and transformation therapy in the treatment of gastric cancer, the overall survival rate of most samples remains low.
During the process of tumorigenesis and development, hypermetabolism and rapid proliferation of tumor cells lead to ischemia and hypoxia inside tumors, so that the tumor cells enter a continuous endoplasmic reticulum stress state. Studies have shown that specific strengths of endoplasmic reticulum stress can affect the development of cancer by a variety of mechanisms, including promoting cancer cell growth and metastasis, angiogenesis, immune escape, and chemo-resistance. Endoplasmic reticulum stress has important influence on the occurrence, progression and treatment of gastric cancer in particular, and can promote the progression of gastric cancer through interaction with helicobacter pylori, EB virus, and also can cause the migration and invasion of gastric cancer cells by promoting the epithelial-mesenchymal transition of gastric cancer cells.
Biomarkers can be useful in predicting prognosis of a cancer sample. In recent years, many studies have used genes as biomarkers for tumor development and prognosis. At present, histological diagnosis and tumor-lymph node-metastasis (TNM) staging remain the main methods for assessing prognosis of gastric cancer. Due to the high heterogeneity of gastric cancer and individual differences in samples, there are large differences in prognosis and treatment efficacy even for samples with similar clinical and pathological characteristics and even the same TNM staging. This suggests that past gastric cancer prognostic evaluation indicators may have expanded to the limit of predicting the outcome of a sample prognosis and the benefit of treatment. Therefore, there is an urgent need to identify new biomarkers to assist in improving the current prognostic indicators and provide the basis for the prognosis evaluation and individualized treatment of gastric cancer.
Disclosure of Invention
Aiming at the problem that the high heterogeneity of the gastric cancer and the individual difference of samples lack accurate prognostic indicators, the invention provides a gastric cancer risk prognosis scoring model of endoplasmic reticulum stress, a construction method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic genes, wherein the endoplasmic reticulum stress genes comprise: NOS3, PON1, CXCR4, MATN3, ANXA5, SERPINE1;
risk score model = (0.052 × NOS3 expression level) + (0.137 × PON1 expression level) + (0.067 × CXCR4 expression level) + (0.131 × MATN3 expression level) + (0.116 × ANXA5 expression level) + (0.09 × SERPINE1 expression level).
A construction method of a gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic genes comprises the following steps:
step 1, obtaining an RNA sequence data set and clinical data from a cancer genome map TCGA (http:// cancer. Gastric cancer samples were obtained from GEO database (http:// www.ncbi.nlm.nih.gov/GEO /);
to ensure comparability of the data, RNA-seqs data was transformed with millions of Transcripts (TPM) and normalized by log2 (TPM + 1) transformation for subsequent analysis;
step 2, acquiring endoplasmic reticulum stress related characteristic genes ERS-RGs from a GeneCards database (https:// www.geneclards.org /); differential expression analysis between gastric cancer tissues and paracarcinoma tissues was performed using the "limma" package in the R software, with P <0.05 and | log2 (Fold Change) | >0 as screening criteria for the inclusion of more comprehensive gastric cancer differential genes; carrying out single-factor Cox regression analysis by using a survivval package in R software, and screening out a gastric cancer differential expression gene related to endoplasmic reticulum stress characteristics with prognostic value;
step 4, performing least absolute shrinkage operator (LASSO) regression analysis on the training set by using a glmnet R program package to construct a multi-gene risk model;
screening genes for constructing a risk score model includes: NOS3, PON1, CXCR4, MATN3, ANXA5, SERPINE1;
constructing an air risk scoring model:
risk score model = (0.052 × NOS3 expression level) + (0.137 × PON1 expression level) + (0.067 × CXCR4 expression level) + (0.131 × MATN3 expression level) + (0.116 × ANXA5 expression level) + (0.09 × SERPINE1 expression level);
step 4, constructing a regression coefficient corresponding to the gene through a model, calculating the risk score of each sample, and dividing the gastric cancer samples into a high-risk group and a low-risk group through the median of the risk scores of the samples; data in the GEO database (http:// www. Ncbi. Nlm. Nih. Gov/GEO /) was used (N = 387) as the validation set; applying the successfully constructed risk scoring model to a verification set for verification;
performing Kaplan-Meier (K-M) curve analysis on the identified high-risk group and low-risk group by using a 'surfminer' program package, and comparing the difference of the total survival time (OS) of the two groups of samples; using a 'timeROC' program package to draw a time-dependent receiver operating characteristic curve (ROC), calculating the Area under the curve (AUC) of the gastric cancer sample at a plurality of time points, and evaluating the capability of the risk model for predicting the prognosis of the gastric cancer sample; the same risk scoring formula and cut-off values are used in the validation set to validate the accuracy of the model.
According to the application of the gastric cancer prognosis risk model based on the endoplasmic reticulum stress characteristic gene in the preparation of the kit.
The kit is applied to products for predicting the overall survival rate of gastric cancer patients.
The kit is applied to diagnosis products of the overall survival rate of gastric cancer patients.
The kit is applied to auxiliary diagnosis products of the overall survival rate of gastric cancer patients.
The invention develops a gastric cancer prognosis risk model with strong practicability by using the endoplasmic reticulum stress related characteristic genes so as to predict the overall survival time of a gastric cancer patient. The present invention analyzes gene expression profiles of gastric cancer patients from the TCGA database and the GEO database. The data collected from the TCGA database was used as a training set, and a total of 375 gastric cancer samples and 32 paracancer samples were included. And verified using 387 gastric cancer samples from the GEO database. Differential Expression Genes (DEG) of gastric cancer tissues and paracarcinoma in TCGA database were screened by R software package "limma". ER stress-associated genes in DEG were identified by GeneCards database. Based on DEG data in a training set, a prognosis model with 6 endoplasmic reticulum stress-related characteristic genes is established by using univariate Cox regression analysis and LASSO regression analysis, and gastric cancer patients are divided into high-risk groups and low-risk groups. Nomograms are constructed by combining clinical characteristics and risk scores to predict the survival probability of gastric cancer patients. The calibration curve verifies good agreement between nomogram predictions and actual observations. The risk score of gastric cancer patients in the training cohort was significantly correlated with OS (p < 0.05).
ROC curve analysis showed that AUC was 0.695, 0.786, and 0.698 at 3, 5, and 8 years of follow-up. Also in the validation set, the 3-year, 5-year and 8-year AUC values were 0.580, 0.625 and 0.627, respectively. The predicted performance has been fully validated. The risk score determined by the risk model is determined by independent prognostic factor analysis as a prognostic factor independent of other clinical pathological characteristics. A risk score based on 6 ER stress-associated genes may well classify gastric cancer patients into high risk, low risk populations, which may aid in the selection of clinical treatment regimens.
Compared with the prior art, the invention has the following advantages:
the invention establishes a prognosis model with 6 genes related to endoplasmic reticulum stress characteristics, and divides a gastric cancer sample into a high risk group and a low risk group. The method has good prediction performance in both a training set and a verification set.
Drawings
FIG. 1 is a volcano plot of differentially expressed endoplasmic reticulum stress-associated signature genes;
FIG. 2 is a forest map of ERS-RGs identified by univariate cox regression analysis as being significantly correlated with prognosis;
FIG. 3 shows the development of a prognostic model based on ERS-RGs in the TCGA training set; FIG. 3 (A-B) identifies 6 ERS-RGs by LASSO regression analysis;
FIG. 4 shows validation of ERS-RGs-based developed prognostic models in the TCGA training set; survival analysis of the feature-defined risk groups in fig. 4 (a); (B) 6 ERS-RGs construct a time-dependent ROC curve of a prognosis model;
FIG. 5 shows validation of a prognostic model developed based on ERS-RGs in the GEO validation set; FIG. 5 (A) survival analysis of feature-defined risk groups; (B) 6 ERS-RGs construct a time-dependent ROC curve of a prognosis model;
FIG. 6 is a nomogram for constructing a survival prediction; FIG. 6 is a forest chart showing the results of single-and multi-factor independent prognostic analyses performed on risk scores; (B) Nomograms incorporating risk scores and clinical information characteristics; (C) The calibration curve shows a high agreement between the nomogram predicted and actual survival rates.
Detailed Description
In order that the manner in which the above recited objects, features and advantages of the present invention are obtained will be readily understood, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It should be noted that the embodiments and features of the embodiments of the present application may be combined with each other without conflict.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, however, the present invention may be practiced otherwise than as specifically described herein and, therefore, the present invention is not limited to the specific embodiments disclosed in the following description.
Example 1
Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene
Step 1, data Source
Transcriptome data and corresponding clinical information for 375 gastric cancer and 32 paracancer samples were obtained from the TCGA database (http:// cancer. Nih. Gov /) and used as training set samples; 387 gastric cancer samples were downloaded from the GEO database (http:// www. Ncbi. Nlm. Nih. Gov/GEO /) as validation set samples (GSE 84437). To ensure comparability of the data, RNA-seqs data were transformed per million Transcripts (TPM) and normalized by log2 (TPM + 1) transformation for subsequent analysis. ERS-related signature genes (ERS-RGs) were obtained from the GeneCards database (https:// www.
Step 2, differential expression analysis and functional enrichment analysis of ERS-RGs
Differential expression analysis between gastric cancer tissue and para-carcinoma tissue was performed using the "Limma" package in R software. To incorporate a more comprehensive gastric cancer differential gene, P <0.05 and | log2 (Fold Change) | >0 were used as screening criteria. The R software package "clusterirprofiler" is used for performing Gene Ontology function (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and visualization on differential Genes, characterizing key pathways involved by gastric cancer differential Genes and disclosing potential molecular mechanisms.
Step 3, constructing a prognosis model and verifying an external data set
Single-factor Cox regression analysis is carried out by using a survivval package in R software, and gastric cancer differential expression genes related to ERS characteristics with prognostic value are screened out. The multigenic risk model was constructed by performing a least absolute shrinkage (LASSO) regression analysis using the "glmnet" package. The risk score of each sample was calculated by the regression coefficient corresponding to the model-constructed gene (risk score = ∑ (regression coefficient × model-constructed gene expression amount)). And taking the median of the risk scores of the samples in the training set as a Cut-off value to divide the samples into two groups with high risk and low risk. A successfully constructed risk scoring model is validated in an external data set (GEO data set). As shown in fig. 5.
Step 4, evaluating the efficiency of the risk model and analyzing the independent prognostic factors
The identified high and low risk groups were subjected to Kaplan-Meier (K-M) curve analysis using the "surfminer" package, comparing the difference in Overall Survival (OS) for the two groups of samples. The method comprises the steps of drawing a time-dependent receiver operating characteristic curve (ROC) by using a 'timeROC' program package, calculating areas under the curve (AUC) of the gastric cancer sample in OS of 3 years, 5 years and 8 years respectively, and further evaluating the capability of a risk model for predicting the prognosis of the gastric cancer sample. To assess whether the risk model has independent prognostic value for assessing the prognosis of gastric cancer samples, single-factor and multi-factor independent prognostic analyses were performed on the risk scores. Independent prognostic factors identified by multifactor independent prognostic analysis were used as variables by the "rms" package to plot nomograms for comprehensive assessment of survival rates of samples for 3, 5 and 8 years.
Step 5, analyzing immune microenvironment state and tumor mutation load
In order to evaluate the immune cell infiltration condition in the gastric cancer tumor microenvironment of the high-risk and low-risk groups, the characteristic immune cell infiltration abundance between the two groups is analyzed by a deconvolution-based CIBERSORT algorithm. The Cytolytic activity score (cytic activity, CYT score) was calculated using the geometric mean of the expression levels of granzyme a (GZMA) and perforin 1 (PRF 1). Tumor Mutation Burden (TMB) is the total number of somatic gene coding errors, base substitutions, gene insertions or deletion errors detected per million bases. TMB was calculated by determining the mutation status of gastric cancer samples by the "maftools" package.
Step 6, statistical methods
All statistical analysis and visualization was based on the R language (Version 4.1.3) and the R package. P values less than 0.05 are considered statistically significant.
Example 2 identification of gastric cancer ERS-associated prognostic genes and construction of Cox Risk model
The analysis of the gastric cancer-health sample differential genes is carried out based on the TCGA training set queue, and 5054 remarkable up-regulated genes and 4229 remarkable down-regulated genes are obtained in total. A total of 785 ERS-associated signature genes (ERS-RGs) were obtained from the GeneCards database. Among them, 444 genes are considered as differentially expressed genes of gastric cancer, including 168 significantly down-regulated genes and 276 significantly up-regulated genes. Functional enrichment of GO and KEGG showed that the differential ERS signature genes were mainly enriched in biological processes like protein processing in the endoplasmic reticulum, ECM receptor interactions and unfolded protein responses (P < 0.05). Based on the 444 ERS characteristic genes differentially expressed in gastric cancer, single-factor Cox regression analysis is performed, as shown in FIG. 2, 12 high-risk genes with significant prognosis are screened out for LASSO regression analysis (HR > 1), as shown in FIG. 3, and the optimal lambda value =6 and the beta regression coefficient of each gene are obtained. Substituting the genes to obtain a risk score model formula as follows: risk score =0.052 × nos3 expression amount +0.137 × pon1 expression amount +0.067 × cxcr4 expression amount +0.131 × matnn 3 expression amount +0.116 × anxa5 expression amount +0.09 × serpine1 expression amount. Samples were divided into two groups, high risk group (N = 169) and low risk group (N = 168) according to the median 2.369 sample risk score in the training set cohort.
Example 3 prognostic efficacy evaluation and validation of risk models
The visualization result of the risk curve shows that the death ratio of the gastric cancer sample in the high risk group is higher than that in the low risk group, and the high risk group sample is suggested to have poor prognosis. NOS3, PON1, CXCR4, MATN3, ANXA5 and SERPINE1 are all highly expressed in the high risk group, which shows that the high expression of the six model construction genes is positively correlated with the high risk.
The Kaplan-Meier curve indicates that the low risk group exhibits higher survival in both the training set (P < 0.0001) and the validation set (P = 0.0013). The time-dependent ROC analysis results showed that 3 year time AUC values =0.695,5 year time AUC values =0.786,8 year time AUC values =0.698 in the TCGA data set; the AUC value =0.625 in the 5-year time in the verification set indicates that the risk model has good sensitivity and specificity for prognosis prediction of the gastric cancer sample, particularly for predicting the 5-year total survival rate of the gastric cancer sample.
Example 4 independent prognostic factor analysis of Risk scores and establishment of nomograms
Age, gender, grade, staging (Stage), and risk score were included as variables in the one-way independent prognostic factor analysis. The one-way independent prognostic analysis results showed that the risk score was a risk factor significantly associated with gastric cancer prognosis (HR =3.601,95% ci. Multifactor independent prognostic analysis results showed that the risk score was a prognostic factor independent of other clinical pathology characteristics (HR =3.598,95% ci. In order to further integrate clinical information and realize multivariate survival analysis of the gastric cancer samples, factors with independent prognostic value determined by the multifactor independent prognostic analysis are included and drawn into a nomogram for comprehensively analyzing the survival rates of the gastric cancer samples for 3 years, 5 years and 8 years. As shown in fig. 6.
Example 5 assessment of ERS status and immune microenvironment status in gastric cancer high and low risk group
The intracellular expression level of related proteins such as ATF6, HSPA5, XBP1 and ATF4 is used as the most common index for detecting ERS intensity in cells or tissues, and the expression level of the markers is detected in 375 gastric cancer samples. The expression level of the characteristic gene in the high risk group is obviously higher (P < 0.05), which indicates that the ER stress intensity of the high risk group is obviously higher than that of the low risk group (P < 0.05). The CIBERSORT results show that the infiltration abundance of immune cells in the tumor microenvironment of the gastric cancer samples of the high-risk group and the low-risk group is different, the abundance of activated CD4 memory T cells of the high-risk group is obviously lower than that of the activated CD4 memory T cells of the low-risk group, and the abundance of macrophages M0 and M2 is obviously higher than that of the low-risk group (P < 0.05). Furthermore, the expression level of common immune checkpoints was significantly higher in the high risk group than in the low risk group (P < 0.05). The cytolytic activity score of the high risk group samples was also significantly elevated (P < 0.05).
Those matters not described in detail in the present specification are well known in the art to which the skilled person pertains. Although illustrative embodiments of the present invention have been described above to facilitate the understanding of the present invention by those skilled in the art, it should be understood that the present invention is not limited to the scope of the embodiments, and various changes may be made apparent to those skilled in the art as long as they are within the spirit and scope of the present invention as defined and defined by the appended claims, and all matters of the invention which utilize the inventive concepts are protected.

Claims (5)

1. A gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic genes is characterized in that: the endoplasmic reticulum stress gene is: NOS3, PON1, CXCR4, MATN3, ANXA5, SERPINE1;
risk score model = (0.052 × NOS3 expression level) + (0.137 × PON1 expression level) + (0.067 × CXCR4 expression level) + (0.131 × MATN3 expression level) + (0.116 × ANXA5 expression level) + (0.09 × SERPINE1 expression level).
2. Use of the model for the risk of prognosis of gastric cancer based on the endoplasmic reticulum stress signature gene according to claim 1 in the preparation of a kit.
3. The kit according to claim 2, for use in a product for predicting the overall survival rate of gastric cancer patients.
4. The use of the kit according to claim 2 in a product for diagnosing the overall survival rate of gastric cancer patients.
5. The use of the kit according to claim 2 in a product for assisting in diagnosing the overall survival rate of a gastric cancer patient.
CN202211185735.7A 2022-09-27 2022-09-27 Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application Withdrawn CN115497552A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211185735.7A CN115497552A (en) 2022-09-27 2022-09-27 Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211185735.7A CN115497552A (en) 2022-09-27 2022-09-27 Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application

Publications (1)

Publication Number Publication Date
CN115497552A true CN115497552A (en) 2022-12-20

Family

ID=84471803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211185735.7A Withdrawn CN115497552A (en) 2022-09-27 2022-09-27 Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application

Country Status (1)

Country Link
CN (1) CN115497552A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115641912A (en) * 2022-12-07 2023-01-24 北京泽桥医疗科技股份有限公司 Biomarker for treating and diagnosing gastric cancer metastasis and identification method thereof
CN116665898A (en) * 2023-06-01 2023-08-29 南方医科大学南方医院 Biomarker for predicting prognosis of gastric cancer based on histone modification regulator characteristics, scoring model and application
CN116844685A (en) * 2023-07-03 2023-10-03 广州默锐医药科技有限公司 Immunotherapeutic effect evaluation method, device, electronic equipment and storage medium

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115641912A (en) * 2022-12-07 2023-01-24 北京泽桥医疗科技股份有限公司 Biomarker for treating and diagnosing gastric cancer metastasis and identification method thereof
CN115641912B (en) * 2022-12-07 2023-04-07 北京泽桥医疗科技股份有限公司 Biomarker for treating and diagnosing gastric cancer metastasis and identification method thereof
CN116665898A (en) * 2023-06-01 2023-08-29 南方医科大学南方医院 Biomarker for predicting prognosis of gastric cancer based on histone modification regulator characteristics, scoring model and application
CN116665898B (en) * 2023-06-01 2024-01-30 南方医科大学南方医院 Biomarker for predicting prognosis of gastric cancer based on histone modification regulator characteristics, scoring model and application
CN116844685A (en) * 2023-07-03 2023-10-03 广州默锐医药科技有限公司 Immunotherapeutic effect evaluation method, device, electronic equipment and storage medium

Similar Documents

Publication Publication Date Title
Litchfield et al. Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
CN109859801B (en) Model for predicting lung squamous carcinoma prognosis by using seven genes as biomarkers and establishing method
CN115497552A (en) Gastric cancer prognosis risk model based on endoplasmic reticulum stress characteristic gene and application
JP2020522690A (en) Method and system for identifying or monitoring lung disease
AU2015289758A1 (en) Methods for evaluating lung cancer status
CN110577998A (en) Construction of molecular model for predicting postoperative early recurrence risk of liver cancer and application evaluation thereof
CN115497562B (en) Pancreatic cancer prognosis prediction model construction method based on copper death related gene
CN111951893B (en) Method for constructing tumor mutation load TMB panel
CN113355419B (en) Breast cancer prognosis risk prediction marker composition and application
CN115410713A (en) Hepatocellular carcinoma prognosis risk prediction model construction based on immune-related gene
CN113517073B (en) Method for constructing survival rate prediction model after lung cancer surgery and prediction model system
CN111863137A (en) Complex disease state evaluation method established based on high-throughput sequencing data and clinical phenotype and application
CN115588507A (en) Prognosis model of lung adenocarcinoma EMT related gene, construction method and application
CN112831562A (en) Biomarker combination and kit for predicting recurrence risk of liver cancer patient after resection
CN116287204A (en) Application of mutation condition of detection characteristic gene in preparation of venous thromboembolism risk detection product
CN115482880A (en) Head and neck squamous carcinoma glycolysis related gene prognosis model, construction method and application
CN113234823B (en) Pancreatic cancer prognosis risk assessment model and application thereof
CN112037863B (en) Early NSCLC prognosis prediction system
Bhandari et al. Comparing continuous and discrete analyses of breast cancer survival information
US20240194294A1 (en) Artificial-intelligence-based method for detecting tumor-derived mutation of cell-free dna, and method for early diagnosis of cancer, using same
CN115862876A (en) Device and computer readable storage medium for predicting lung adenocarcinoma patient prognosis and medication guidance based on immune microenvironment gene group
CN115331812A (en) Establishment and verification method of serous ovarian cancer prognostic marker model
Zhong et al. Distinguishing kawasaki disease from febrile infectious disease using gene pair signatures
Cheng et al. Early signatures of breast cancer up to seven years prior to clinical diagnosis in plasma cell-free DNA methylomes
Liu et al. Differentially expressed mutant genes reveal potential prognostic markers for lung adenocarcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20221220